The Impact of Low-Dose Esketamine Combined With Ciprofol on the Quality of Early Postoperative Recovery Among Elderly Patients Undergoing Painless Gastroscopy

Launched by NORTHERN JIANGSU PEOPLE'S HOSPITAL · Sep 25, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a combination of low-dose esketamine and ciprofol affects the recovery of elderly patients after a painless gastroscopy, which is a procedure to examine the stomach and intestines. The researchers want to see if this combination can help patients recover more quickly and safely after the procedure. The trial will include participants aged 60 to 75 who are scheduled for this type of examination and have no major health issues that could complicate the procedure.

To be eligible for the trial, participants must be generally healthy, without significant heart, liver, lung, or kidney problems, and must be able to take part in assessments about their recovery. This means that they should not have any major organ dysfunction, mental health issues, or allergies to the medications being tested. If you or someone you know fits these criteria, participating in this trial may offer an opportunity to contribute to important research while receiving care for a common procedure. Participants will be informed about what to expect during the trial and will need to provide consent to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Scheduled painless gastroscopy examination and treatment
• • 2. Age 60-75 years old
• • 3. ASA grade Ⅰ-Ⅱ
• • 4. The respiratory tract is unobstructed and there is no difficult airway
• • 5. No history of allergy to etomidate and cyclopropofol
• • 6. Participants with normal heart, liver, lung, and kidney functions
• • 7. Able to complete the QoR-15, MMSE, and HADS scale assessments
• • 8. lnformed consent, voluntary participation in the trial, and signed by the patient informed consent
• Exclusion Criteria:
• • 1. Participants with concurrent dysfunction of major organs.
• • 2. Participants with a history of mental illness and abuse of sedative drugs
• • 3. Participants with allergies or contraindications to the study drugs
• • 4. Participants with severe visual, auditory, or speech communication impairments
• • 5. Participants with acute gastrointestinal inflammation or obstruction
• • 6. History of uncontrolled diabetes, hypertension, and hypotension
• • 7. Participants with malignant tumors, severe hyperkalemia, bronchial asthma, or excessive obesity (BMI \> 30kg/m2)
• • 8. Participants with aneurysmal vascular diseases of the thoracic and abdominal aorta, intracranial and peripheral arterial vessels.
• • 9. Unable to cooperate with the QoR-15, MMSE, and HADS scale assessments